IAP Family Proteins and Cancer

IAP 家族蛋白质与癌症

• 批准号: 9042222
• 负责人: Guy S. Salvesen
• 金额: $ 40.46万
• 依托单位: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-04-01 至 2017-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9042222
• 关键词: Address; Apoptosis; Apoptotic; Automobile Driving; BIRC4 gene; Binding; Biochemical; Biochemistry; Biological; CASP8 gene; Caspase; Caspase Inhibitor; Cell Death; Cell Death Signaling Process; Cell Proliferation; Cell Survival; Cells; Cellular biology; Cessation of life; Chemicals; Chromosomal Duplication; Chromosomal translocation; Complex; Data; Deubiquitination; Event; Family member; Future; Gene Amplification; Genes; Hematologic Neoplasms; Human; Ligase; Link; Lysine; Malignant Neoplasms; Mediating; NF-kappa B; Nature; Pathway interactions; Phosphotransferases; Play; Polyubiquitin; Polyubiquitination; Post-Translational Protein Processing; Protein Family; Proteins; Recruitment Activity; Resistance; Role; Signal Transduction; Solid Neoplasm; Specificity; TNF gene; TNF receptor-associated factor 1; TNFR1 Signaling Pathway; TNFRSF1A gene; TRAF2 gene; Testing; Therapeutic; Tumor Necrosis Factor Receptor; Tumor Suppressor Proteins; Ubiquitin-Conjugating Enzymes; Ubiquitination; adapter protein; base; cancer cell; cancer therapy; cell motility; cytotoxicity; improved; in vivo; inhibitor-of-apoptosis protein; inhibitor/antagonist; insight; multicatalytic endopeptidase complex; novel strategies; protein complex; research study; ubiquitin-protein ligase

DESCRIPTION (provided by applicant): Inhibitor of Apoptosis Proteins (IAPs) are commonly over-expressed in cancers, suppressing apoptosis through diverse mechanisms. Conversely, certain endogenous inhibitors of IAPs, particularly the gene encoding ARTS (Septin4), appear to operate as tumor suppressors whose expression becomes lost in certain malignancies. IAP family members XIAP, c-IAP1, and c-IAP2 are E3 ligases, catalyzing formation of polyubiquitin chains on substrates involving either lysine 48 (K48) or K63 linkages, where K48 targets proteins for proteasome- mediated degradation while K63 is a post-translational modification associated with formation of signaling complexes. The biological consequences of partnering of IAPs with K48- versus K63-specific UBCs are profound, having important implications for understanding mechanisms of apoptosis resistance of cancers. For example, c-IAP1 and c-IAP2 associate with Tumor Necrosis Factor (TNF) Receptor complexes to promote K63-linked ubiquitinylation of Rip1, a post-translational modification that suppresses Rip1-mediated cytotoxicity and that stimulates NF-κB activation, thereby aiding cell survival, cell proliferation and cell migration. This proposal addresses the mechanisms that control the IAPs and their roles in apoptosis suppression and signal transduction in cancer. The central hypothesis to be tested is that mechanisms controlling the diverse E3 ligase activities of IAPs play a critical role in regulating both the levels of these proteins and their cellular activities. Specific Aims include: (1) Determining how chemical antagonists of IAPs (based on mimicking SMAC) stimulate their self-directed K48-linked polyubiquitination and proteasome-dependent degradation; (2) Exploring the influence of IAP interactions with the kinase Rip1 on their K63-directed E3 ligase activity and testing the hypothesis that Rip1 binding is key to conversion from K48 to K63-specific ligase activity; (3) Addressing the mechanisms by which c-IAP1 and c-IAP2 operate antagonistically with Deubiquitinase CYLD to modulate K63 ubiquitination of Rip1, thereby dictating the assembly of TNFR1 signaling complexes that either promote or suppress TNFα-induced apoptosis; and (4) Investigating the mechanisms by which ARTS, an endogenous antagonist of XIAP, exerts its tumor suppressor effect. Altogether, the proposed studies will reveal the biochemical and cellular mechanisms underlying the multi-functional nature of IAPs as regulators of cell death and signal transduction, suggesting novel strategies for therapeutic applications to cancer treatment.

描述（由申请人提供）：细胞凋亡蛋白抑制剂（IAP）通常在癌症中过表达，通过多种机制抑制细胞凋亡。相反，IAP的某些内源性抑制剂，特别是编码ARTS（Septin 4）的基因，似乎作为肿瘤抑制剂起作用，其表达在某些恶性肿瘤中丢失。IAP家族成员XIAP、c-IAP 1和c-IAP 2是E3连接酶，催化在涉及赖氨酸48（K48）或K63键的底物上形成聚泛素链，其中K48靶向蛋白质以进行蛋白酶体介导的降解，而K63是与信号传导复合物形成相关的翻译后修饰。IAP与K48特异性UBC和K63特异性UBC结合的生物学后果是深远的，对理解癌症细胞凋亡抗性机制具有重要意义。例如，c-IAP 1和c-IAP 2与肿瘤坏死因子（TNF）受体复合物结合，促进Rip 1的K63连接的泛素化，这是一种翻译后修饰，可抑制Rip 1介导的细胞毒性并刺激NF-κB活化，从而有助于细胞存活、细胞增殖和细胞迁移。该提案涉及控制IAP的机制及其在肿瘤细胞凋亡抑制和信号转导中的作用。待检验的中心假设是，控制IAP的不同E3连接酶活性的机制在调节这些蛋白质的水平及其细胞活性方面起着关键作用。具体目标包括：（1）确定IAP的化学拮抗剂（2）探索IAP与激酶Rip 1的相互作用对其K63定向的E3连接酶活性的影响，并验证Rip 1结合是K48特异性连接酶活性转化为K63特异性连接酶活性的关键的假设;（3）探讨c-IAP 1和c-IAP 2与去泛素化酶CYLD拮抗作用调节Rip 1的K63泛素化的机制，从而决定TNFR 1信号复合物的组装，促进或抑制TNFα诱导的细胞凋亡;（4）研究XIAP的内源性拮抗剂ARTS发挥其肿瘤抑制作用的机制。总之，拟议的研究将揭示的生物化学和细胞机制的多功能性的IAP作为调节细胞死亡和信号转导，建议新的策略，治疗应用于癌症治疗。

项目成果

TNFR-associated factor 2 deficiency in B lymphocytes predisposes to chronic lymphocytic leukemia/small lymphocytic lymphoma in mice.

• DOI: 10.4049/jimmunol.1200814
• 发表时间: 2012-07-15
• 期刊: Journal of immunology (Baltimore, Md. : 1950)
• 作者: Pérez-Chacón G;Llobet D;Pardo C;Pindado J;Choi Y;Reed JC;Zapata JM
• 通讯作者: Zapata JM